Paul Catchpole, Director of Value & Access at the ABPI, comments on the Cancer Research UK report on molecular diagnostic provision in England which was published today.
19 Aug 2015 Posted in ABPI statement By Paul Catchpole
Paul Catchpole said: "ABPI welcomes the report from Cancer Research UK (CRUK) regarding molecular diagnostic tests in cancer. The report clearly sets out the current deficiencies in the testing services in England, meaning that patients are not able to get timely and appropriate access to the most effective medicines and treatments that can improve survival rates and quality of life. These deficiencies urgently need to be addressed through the development, funding, and commissioning of a comprehensive service. Importantly the report also highlights that the rapid development of stratified medicines and their associated tests, not only in cancer but increasingly within other therapy areas, will be held back to the detriment of future patients unless there is much greater national coordination and focus on this vital underpinning service".
For further information, please click here to view the press release from CRUK
Alternatively, please click here to view the blog by Emlyn Samuel, senior policy manager at CRUK.
The ABPI represents innovative research-based biopharmaceutical companies, large, medium and small, leading an exciting new era of biosciences in the UK.
Our industry, a major contributor to the economy of the UK, brings life-saving and life-enhancing medicines to patients. Our members supply 90 per cent of all medicines used by the NHS, and are researching and developing over two-thirds of the current medicines pipeline, ensuring that the UK remains at the forefront of helping patients prevent and overcome diseases.
The ABPI is recognised by government as the industry body negotiating on behalf of the branded pharmaceutical industry, for statutory consultation requirements including the pricing scheme for medicines in the UK.
ABPI Press Office
Telephone: +44 (0) 20 7747 1410 or +44 (0) 20 7747 1441
Mobile: +44 (0) 7850 312064 or +44 (0) 7808 641811